Galapagos Defends High-Risk High-Reward R&D Strategy
CEO: 'We don't want to throw away the baby with the bathwater'
Following a trio of high-profile setbacks, the Belgian biotech is looking to fill the gap between the European launches of its rheumatoid arthritis drug Jyseleca and its programs back in Phase II via in-licensing and M&A.
